Durvalumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Durvalumab
Monoclonal antibody
Type ?
Source Human
Target CD274
Identifiers
CAS Number 1428935-60-7
ATC code none
IUPHAR/BPS 7985
Chemical data
Formula C6502H10018N1742O2024S42
Molecular mass 146.3 kg/mol

Durvalumab[1] is a monoclonal antibody being investigated for the treatment of cancer.[2] It targets programmed death ligand-1 (PD-L1).[3]

This drug was developed by MedImmune.

Clinical trials

A phase 1B clinical trial of durvalumab and tremelimumab showed some activity in non-small cell lung cancer (NSCLC).[3]

Phase 1 data in advanced metastatic urothelial bladder (Study 1108) has led to FDA breakthrough therapy designation.[4]

Early results of a phase I trial combining durvalumab and gefitinib in lung cancer patients "showed promise".[5]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Durvalumab, American Medical Association.
  3. ↑ 3.0 3.1 Astrazeneca’s combination of durvalumab with tremelimumab shows clinical activity in non-small cell lung cancer irrespective of PD-L1 status. Feb 2016
  4. ↑ AstraZeneca's (AZN) Durvalumab Granted FDA Breakthrough Therapy Designation. StreeInsider.com Corporate News, FDA, Management Comments. February 17, 2016.
  5. ↑ Clinical Trial Points to Promising Drug Combo for Lung Cancer and Mesothelioma Patients. May 2016

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Durvalumab&oldid=722336281"